Biotech Stocks and Longevity Investing: Trends to Track

Loading paragraph…

Loading paragraph…

Loading paragraph…

For individual investors tracking the intersection of biotech stocks and longevity, the data points in the same direction across many angles: drug performance, new-drug pipelines, private capital, government support, and demographics. The question is no longer whether longevity is a viable investment theme but how much of the opportunity is already priced in and how much is still ahead.

FAQs

What are biotech stocks?

What is longevity investing?

Why did biotech stocks perform well in 2025?

Sources

• The Association of Investment Companies (2025). “M&A activity drives momentum in biotech and healthcare.”
• BioSpace (2026). “The Five Biggest Biopharma Takeovers of 2025.”
• BioXconomy (2025). “BioXconomy’s top 10 M&A deals of 2025.”
• Businesswire (2025). “Loyal Receives FDA Acceptance of Reasonable Expectation of Effectiveness for Senior Dog Lifespan Extension.”
• Centers for Medicare and Medicaid Services (2025). “NHE Fact Sheet.”
• Drug Discovery and Development (2025). “Top 25 drugs by sales: 2025 H1”
• Evaluate (2025). “Obesity and GLP-1 Dealmaking: Strategic Trends and Market Signals.”
• Evaluate (2025). “Portfolio Tactics to Scale the $300bn Patent Cliff.”
• FDA (2026). “New Drug Therapy Approvals 2025.”
• FierceBiotech (2025). “2025 M&A up in value and deal count after year of ‘conservatism and recovery’: Leerink Partners.”
• JPMorgan (2026). “Biopharma and medtech activity in Q4 2025.”
• Longevity.Technology (2025). “Longevity investment more than doubled to $8.5bn in 2024.”
• Longevity.Technology (2026). “FDA rewrites drug approval rules and longevity stands to gain.”
• Nature Biotechnology (2025). “Are GLP-1s the first longevity drugs?”
• Swiss Re (2025). “GLP-1 drugs may reduce mortality by up to 6.4% in the US by 2045.”
• Vision Lifesciences (2026). “Pharma M&A Tracker 2026: Every Major Deal, Decoded.”

About the Author

Jack Caporal is the Research Director for The Motley Fool and Motley Fool Money. Jack leads efforts to identify and analyze trends shaping investing and personal financial decisions across the United States. His research has appeared in thousands of media outlets including Harvard Business Review, The New York Times, Bloomberg, and CNBC, and has been cited in congressional testimony. He previously covered business and economic trends as a reporter and policy analyst in Washington, D.C. He serves as Chair of the Trade Policy Committee at the World Trade Center in Denver, Colorado. He holds a B.A. degree in International Relations with a concentration in International Economics from Michigan State University.

TMFJackCap

Jack Caporal has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.

Read Next

Stock Performance in Every Recession Since 1980

The State of LGBTQ Finance: A Survey of 2,000 Americans

ESG, SRI, Impact Investing: What Are They, How to Get Started, and How Funds Have Performed

State of Streaming 2025: Streaming Services and Consumer Sentiment

An Introduction to Digital Real Estate in the Metaverse

Average Net Worth by Age, Education, and Race